Tokyo, Japan, September 24, 2026 - United Immunity Co., Ltd., a clinical stage biotechnology company, today announced that it has raised a total of ¥2.2 billion in private financing,. comprising ¥1.8 billion through a third-party allotment of new shares and ¥0.4 billion through debt financing.
In addition, the company’s project, “Development of in vivo CAR-Macrophage Therapy for Refractory Solid Tumors,” has been selected for the Strengthening Program for Pharmaceutical Startup Ecosystem (V-eco) of the Japan Agency for Medical Research and Development (AMED).
By combining the ¥2.2 billion in private financing raised in this round with up to approximately ¥2.8 billion in public grant funding, the company expects to have access to up to ¥5.0 billion in total development funding to accelerate research and clinical development of its lead program UI-102 and in vivo macrophage engineering programs for the treatment of solid tumors and fibrotic diseases.
The company will also consider additional financing, as needed, to accelerate and expand new research and development programs in therapeutic areas beyond oncology.
“This financing will enable us to strengthen our foundation as a drug-discovery company to operate globally and to significantly enhance our R&D capabilities to bring new treatment options to patients" said Masato Kishida CEO. "We are deeply grateful to the corporations, investors, financial institutions, AMED, and all other stakeholders who have supported us. United Immunity will continue working to deliver to patients around the world innovative in vivo immunotherapies originating in Japan and born from the convergence of immunology and nanoparticle technology".
Investors and financing providers in this round (in no particular order): ITOCHU Corporation; Ono Venture Investment, Inc. (Ono Pharmaceutical CVC); Ricoh Biomedical Startup Investment Limited Partnership (Ricoh CVC); Saisei Bioventures L.P.; UTEC 5 Investment Limited Partnership (The University of Tokyo Edge Capital Partners); Mizuho Life Science No. 1 Investment Limited Partnership (Mizuho Capital); MUFG Life Science No. 2 Investment Limited Partnership (Mitsubishi UFJ Capital); Miyako Kyoto University Innovation No. 3 Investment Limited Partnership (Miyako Capital); Fujita TT Impact No. 1 Investment Limited Partnership (Fujita Innovation Capital / Tokai Tokyo Investment); NVCC No. 10 Investment Limited Partnership (Nippon Venture Capital Corporation); KUC No. 1 Investment Limited Partnership (Kobe University Capital); Aozora HYBRID No. 3 Investment Limited Partnership (Aozora Corporate Investment); The Joyo Bank, Ltd. PDF